For targeting GRPR, RM-26 (GRPR antagonist) and its dual-targeting radiotracers (RGD-RM26-03, denoted as LNC1015) have showed favorable pharmacokinetics and high clinical feasibility for PET/CT imaging of cancer 120-124. This evidence concerns the gene GRPR and cancer.